Estimates of survival for patients across GRIPHON and open-label extension studies (95% CI)2†
UPTRAVI® (selexipag) demonstrated consistent, long-term safety across GRIPHON (N=1156) and open-label extension1,3
These data are from long-term follow-up and an open-label extension study. These uncontrolled observations do not allow comparison with a control group not given UPTRAVI® and cannot be used to determine the long-term effect of UPTRAVI® on mortality.
At Year 10, 408 patients had been censored. Participant is said to be censored when information on time to event is not available due to loss to follow-up or non-occurrence of outcome event before the trial end.2,4
A long-term follow-up was conducted in patients who were treated with UPTRAVI® in the pivotal trial and OLE (N=574).2
